Many drug failures are really drug delivery failures

Many drugs fail in clinical trials not because they do not work, but because they lack a proper delivery mechanism. Pankaj Karande, a Rensselaer Polytechnic Institute assistant professor of chemical and biological engineering, understands this and is trying to solve this delivery problem at its most confounding level--the brain. "You can have the best and most promising of drugs, but if it doesn't go where it is needed, then it won't be effective," Karande says in a profile on RPI's website. "There are a lot of new discoveries within the area of drug development, even related to treatment of Alzheimer's. There is not a drug discovery problem; drug delivery is really the challenge." Karande is working with grants from the Alzheimer's Association to find ways of bypassing the challenging blood-brain barrier to get medicines to their intended targets. Profile

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.